Biocon Ltd.
Price
Daily candles · NSEPrice history isn’t available for this scrip.
What the numbers say
- Low return on equity: 3-year ROE 5.1%.
- Comfortable leverage: debt-to-equity of 0.44.
- Sales compounded at 14.8% over 3 years.
- Profits convert to cash well (CFO/OP 0.73).
- Trades above its industry P/E (117.1 vs 25.9).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- Biocon secures supply contract for Pertuzumab in Brazil
The consortium of Biocon, Bahiafarma and Bionovis received 100% allocation under Brazil's 10-year PDP program for Pertuzumab
- Biocon’s arm secures marketing approval for pegfilgrastim biosimilar in Japan
This approval further strengthens the company’s portfolio of biosimilar products in Japan
- Biocon reports over 4-fold jump in Q1 consolidated net profit
The total consolidated income of the company has increased by 9.17% at Rs 4,390.50 crore for Q1FY27
- Biocon launches Yesafili in United States
Yesafili (aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg
- Biocon’s arm secures Health Canada’s nod for Yesintek (ustekinumab) Autoinjector Pen
This approval further strengthens the company’s portfolio of immunology products in Canada
- Biocon gets EMA’s nod for new drug product fill finish line for Semglee at Malaysia facility
Supplies to Europe from this line are expected to begin from Q2FY27
- Mylan Inc. exits Biocon through Rs 3,679 crore open market deals
Mylan Inc. has divested its entire 5.64% stake in Biocon
- Biocon’s partner secures multiple insulin contracts in Malaysia
Duopharma Biotech has secured multiple insulin contracts from Ministry of Health, Malaysia, valued at over 225 million Malaysian ringgit
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 16,927 | 15,262 | 14,756 | 11,174 | 8,184 |
| Other income | 456 | 1,356 | 968 | 768 | 690 |
| Total Income | 17,383 | 16,618 | 15,723 | 11,942 | 8,874 |
| Expenditure | 13,585 | 12,243 | 11,559 | 9,055 | 6,691 |
| Operating Profit | 3,798 | 4,375 | 4,164 | 2,888 | 2,183 |
| Interest | 990 | 897 | 974 | 419 | 68 |
| Depreciation | 1,957 | 1,687 | 1,569 | 1,113 | 814 |
| Profit before tax | 448 | 1,887 | 1,525 | 897 | 983 |
| Tax | 79 | 457 | 227 | 254 | 212 |
| Net Profit | 369 | 1,429 | 1,298 | 643 | 772 |
| EPS (₹) | 2.82 | 8.46 | 8.55 | 3.88 | 5.44 |
| Net margin % | 2.2 | 9.4 | 8.8 | 5.8 | 9.4 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 811 | 600 | 600 | 600 | 600 |
| Reserves | 32,706 | 20,618 | 18,862 | 16,992 | 7,627 |
| Net worth | 33,517 | 21,218 | 19,463 | 17,592 | 8,228 |
| Total sources | 49,340 | 44,106 | 40,320 | 43,150 | 16,514 |
| Net block | 36,486 | 31,963 | 30,644 | 29,468 | 6,569 |
| Capital work in progress | 6,987 | 8,508 | 7,993 | 7,317 | 4,110 |
| Investments | 3,132 | 2,229 | 2,253 | 3,950 | 2,257 |
| Inventory | 6,086 | 4,931 | 4,944 | 4,244 | 2,298 |
| Debtors | 5,987 | 5,488 | 6,231 | 3,573 | 2,058 |
| Cash & bank | 3,194 | 4,120 | 2,259 | 2,400 | 1,748 |
| Book value (₹) | 206.76 | 176.73 | 162.11 | 146.53 | 68.53 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 1,994 | 4,061 | 2,954 | 1,853 | 1,177 |
| From investing | -2,082 | -234 | -1,005 | -14,282 | -1,699 |
| From financing | -924 | -1,854 | -2,333 | 13,049 | 242 |
| Net change in cash | -1,012 | 1,973 | -383 | 619 | -280 |
| Free cash flow | -88 | 3,827 | 1,949 | -12,429 | -523 |
| Closing cash | 2,112 | 2,924 | 920 | 1,295 | 654 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 3.3 | 7.4 | 7.0 | 5.4 | 8.3 |
| ROE % | 1.3 | 7.0 | 7.0 | 5.0 | 9.8 |
| PAT margin % | 2.2 | 9.3 | 8.7 | 5.7 | 9.4 |
| EBIT margin % | 8.4 | 18.2 | 16.7 | 11.7 | 12.8 |
| Debt / equity | 0.44 | 0.84 | 0.81 | 1.01 | 0.60 |
| Current ratio | 1.22 | 1.14 | 0.99 | 1.45 | 2.19 |
| Interest cover | 1.45 | 3.10 | 2.57 | 3.14 | 15.54 |
| Sales growth % | 10.9 | 3.4 | 32.1 | 36.5 | 14.6 |
| Dividend per share (₹) | 0.50 | 0.50 | 0.50 | 1.50 | 0.50 |
| Payout % | 21.0 | 5.9 | 5.9 | 38.9 | 9.3 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Biocon Ltd. (BIOCON) last traded at ₹330.30 on the NSE, down +1.40% on the session. Prices on this page are indicative and for information only.
Biocon Ltd. has traded between ₹328.35 and ₹447.15 over the last 52 weeks on the NSE.
Biocon Ltd. has a market capitalisation of about ₹53,542 crore.
Biocon Ltd. trades at a P/E of 117.1, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for BIOCON from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Biocon Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in